Senior Microbiome Scientist: Metaproteomics Lead

Quadram Institute; United Kingdom; On-site; GBP 45,000 - 57,000; Full time

Job summary

A leading research institute in the UK seeks a Senior Research Scientist to focus on microbiome and metabolic studies. The role involves planning experiments, leading scientific direction, and collaborating with team members and external partners. Candidates must have a PhD and a strong background in microbiome-related research. The position offers a competitive salary between £45,450 and £56,750, with a full-time commitment until March 2028.

Qualifications

• Essential: PhD in Biochemistry, Microbiology, Molecular Biology or relevant fields.
• Experiences with laboratory microbiome studies and metaproteomics.
• Good understanding of microbiome intervention trials.

Responsibilities

• Identify and plan experiments to meet project objectives.
• Lead scientific direction and manage project budgets.
• Prepare documentation for ethics approval.
• Produce high-quality reports and manuscripts for publication.
• Mentor less experienced researchers and provide guidance.

Skills

Experimental microbiology relevant to live microbiome studies

Bioinformatic analysis of data

Microbiome intervention trials

Metagenomics

Metaproteomics

Preparing data/information and draft grant proposals

Demonstrated research performance

Oral research presentations

Preparing documents for ethics approval

Scientific writing record

Supervision of students, postdocs and visiting workers

Technical training

Education

PhD in Biochemistry, Microbiology, Molecular Biology or relevant fields

Job description

A leading research institute in the UK seeks a Senior Research Scientist to focus on microbiome and metabolic studies. The role involves planning experiments, leading scientific direction, and collaborating with team members and external partners. Candidates must have a PhD and a strong background in microbiome-related research. The position offers a competitive salary between £45,450 and £56,750, with a full-time commitment until March 2028.